Distribution and Use Records Clause Samples

Distribution and Use Records. Supplier shall maintain and give Bayer access, upon advance notice and at reasonable times, to, for a period of not less than fifteen (15) years from production, donor records and test results with respect to each unit of plasma included in PPF delivered to Bayer. Such records and results shall be maintained such that they can rapidly and unequivocally be accounted for and made available to Bayer within fourteen (14) days from the date of request. Bayer shall maintain and give Supplier access, upon advance notice and at reasonable times, to, for a period of not less than fifteen (15) years from the date of delivery, records identifying the use of each lot of PPF and the Products into which such PPF was processed (including without limitation, Kogenate®). Such records shall be maintained such that the use of each lot of PPF can be rapidly and unequivocally accounted for and made available to Supplier within fourteen (14) days from the date of request. Bayer shall assist Supplier in identifying, tracking and controlling the use of any PPF identified in post-donation information as contaminated or otherwise unsuitable for processing into Products.
View SourceView Similar (3)
Distribution and Use Records. (i) Purchaser shall maintain and give Bayer access upon advance notice and at reasonable times, to, for a period of not less than fifteen (15) years from production, donor records and test results with respect to each unit of the Inputs delivered to Bayer. Such records and results shall be maintained such that they can rapidly and unequivocally be accounted for and made available to Bayer within fourteen (14) days from the date of request. (ii) Records of the use of each lot of the Inputs delivered to Bayer shall be maintained by Bayer for a period of not less than fifteen (15) years from the date of delivery. Such records shall be maintained such that the use of each lot of the Inputs can be rapidly and unequivocally accounted for and the Products into which such Inputs were processed, identified and made available to Purchaser within fourteen (14) days from the date of request. Purchaser shall assist Bayer in identifying, tracking and controlling the use of any Inputs identified in post-donation information as contaminated or otherwise unsuitable for processing into Products. (iii) Records regarding the testing, storage, distribution and disposal of the Products shall be maintained by Purchaser for such period required by the Regulations.
View SourceView Similar (2)
Distribution and Use Records. Talecris GmbH maintain and give ▇▇▇▇▇ access, upon advance notice and at reasonable times, to, for a period of not less than thirty (30) years from production, donor records and test results with respect to each unit of plasma included in the Contractual Products delivered to ▇▇▇▇▇. Such records and results shall be maintained in a manner that assures that they can rapidly and unequivocally be accounted for and made available to ▇▇▇▇▇ no later than fourteen (14) days from the date of request. ▇▇▇▇▇ shall maintain and give Talecris GmbH access, upon advance notice and at reasonable times, to, for a period of not less than thirty (30) years from the date of delivery, records identifying the use of Contractual Products and sale to Talecris GmbH of the Finished Products. Such records and results shall be maintained in a manner that assures that they can rapidly and unequivocally be accounted for and made available to Talecris GmbH no later than fourteen (14) days from the date of request. ▇▇▇▇▇ shall assist Talecris GmbH in identifying, tracking and controlling the use of any Contractual Products identified in post donation information as contaminated or otherwise unsuitable for use. Notwithstanding the foregoing, neither Party will destroy any such records and results without first notifying the other Party.
View SourceView Similar (2)
Distribution and Use Records. Releasor shall maintain and give Distributor access, upon advance notice and at reasonable times, to, for such period as required by applicable Regulations, donor records and test results with respect to each unit of plasma included in the Products delivered to such Distributor. Such records and results shall be maintained in a manner that assures that they can rapidly and unequivocally be accounted for and made available to a Distributor no later than fourteen (14) days from the date of request. Each Distributor shall maintain and give Newco access, upon advance notice and at reasonable times for a period not less than that required by applicable Regulations, records identifying the use and sale of the Products, including without limitation, records indicating each sale of Products by lot number, customer, volume and dollar amounts, as well as customer relationship records, including customer complaints, disputes and resolutions of any of the foregoing. Such records and results shall be maintained in a manner that assures that they can rapidly and unequivocally be accounted for and made available to Releasor no later than fourteen (14) days from the date of request. Each Distributor shall assist Releasor in identifying, tracking and controlling the use of any Products identified in post-donation information as contaminated or otherwise unsuitable for use.
View Source
Distribution and Use Records. Talecris/ Precision shall maintain and give Customer access, upon advance notice and at reasonable times, to, production, donor records and test results with respect to each unit of plasma included in Cryo delivered to Customer. Such records and results shall be maintained such that they can rapidly and unequivocally be accounted for and made available to Customer within fourteen (14) days from the date of request. All such records will be maintained by Talecris for a time period at or greater than required by the FDA. Customer shall maintain and give Talecris access, upon advance notice and at reasonable times, to, records identifying the use of each lot of Cryo and the Products from which such Cryo was processed. Such records shall be maintained such that the use of each lot of Cryo can be rapidly and unequivocally accounted for and made available to Talecris within fourteen (14) days from the date of request. All such records will be maintained by Customer for a time period at or greater than required by the FDA. Customer shall assist Talecris in identifying, tracking and controlling the use of any Cryo identified in post-donation information as contaminated or otherwise unsuitable for processing into Products.
View Source

Related to Distribution and Use Records

  • Distribution of Literature FSFSA representatives may, during non-working hours or during any breaks, distribute employee organization literature. The FSFSA agrees that nothing of a libelous, racist, sexist, obscene, or partisan political nature shall be so distributed.

  • Disposition of Books, Records and Canceled Certificates DST may send periodically to the Fund, or to where designated by the Fund, all books, documents, and all records no longer deemed needed for current purposes, upon the understanding that such books, documents, and records will be maintained by the Fund under and in accordance with the requirements of applicable federal securities laws. Such materials will not be destroyed by the Fund without the consent of DST (which consent will not be unreasonably withheld), but will be safely stored for possible future reference.

  • Distribution of Reports to the Trustee and the Company; Advances by the Master Servicer. (See Section 4.04 of the Standard Terms)

  • Time Records The employer will keep a record for a continuous period of seven (7) years from which can be readily ascertained the following:

  • Notification and Distribution of Materials The Company shall notify the Holders in writing of the effectiveness of the Resale Shelf Registration Statement as soon as practicable, and in any event within one (1) Business Day after the Resale Shelf Registration Statement becomes effective, and shall furnish to them, without charge, such number of copies of the Resale Shelf Registration Statement (including any amendments, supplements and exhibits), the Prospectus contained therein (including each preliminary prospectus and all related amendments and supplements) and any documents incorporated by reference in the Resale Shelf Registration Statement or such other documents as the Holders may reasonably request in order to facilitate the sale of the Registrable Securities in the manner described in the Resale Shelf Registration Statement.